JP2011516279A - 炎症イメージング用の新規な混合配位子コア／シェル型酸化鉄ナノ粒子 - Google Patents

炎症イメージング用の新規な混合配位子コア／シェル型酸化鉄ナノ粒子 Download PDF

Info

Publication number
JP2011516279A
JP2011516279A JP2010549132A JP2010549132A JP2011516279A JP 2011516279 A JP2011516279 A JP 2011516279A JP 2010549132 A JP2010549132 A JP 2010549132A JP 2010549132 A JP2010549132 A JP 2010549132A JP 2011516279 A JP2011516279 A JP 2011516279A
Authority
JP
Japan
Prior art keywords
nanostructure
ligand
nanoparticle core
inorganic nanoparticle
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010549132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516279A5 (enExample
Inventor
グリモンド，ブライアン
ベールズ，ブライアン・シー
チアキ，トレイナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Electric Co
Original Assignee
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Electric Co filed Critical General Electric Co
Publication of JP2011516279A publication Critical patent/JP2011516279A/ja
Publication of JP2011516279A5 publication Critical patent/JP2011516279A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1836—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Polyethers (AREA)
JP2010549132A 2008-03-05 2009-03-04 炎症イメージング用の新規な混合配位子コア／シェル型酸化鉄ナノ粒子 Pending JP2011516279A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/042,701 2008-03-05
US12/042,701 US20090226376A1 (en) 2008-03-05 2008-03-05 Novel Mixed Ligand Core/Shell Iron Oxide Nanoparticles for Inflammation Imaging
PCT/EP2009/052523 WO2009109588A2 (en) 2008-03-05 2009-03-04 Mixed ligand core/shell iron oxide nanoparticles for inflammation imaging

Publications (2)

Publication Number Publication Date
JP2011516279A true JP2011516279A (ja) 2011-05-26
JP2011516279A5 JP2011516279A5 (enExample) 2013-03-14

Family

ID=40940602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549132A Pending JP2011516279A (ja) 2008-03-05 2009-03-04 炎症イメージング用の新規な混合配位子コア／シェル型酸化鉄ナノ粒子

Country Status (5)

Country Link
US (1) US20090226376A1 (enExample)
EP (1) EP2247315A2 (enExample)
JP (1) JP2011516279A (enExample)
CN (1) CN102083471B (enExample)
WO (1) WO2009109588A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102175448B1 (ko) * 2020-04-13 2020-11-06 주식회사 지티아이바이오사이언스 중원자-할로겐 화합물이 도핑된 산화철 자성 나노입자
KR102175449B1 (ko) * 2020-04-13 2020-11-06 주식회사 지티아이바이오사이언스 산화철/중원자-할로겐 화합물의 코어/쉘 구조 자성 나노입자
WO2021210776A1 (ko) * 2020-04-13 2021-10-21 주식회사 지티아이바이오사이언스 산화철 자성 입자
WO2022270783A1 (ko) * 2021-06-23 2022-12-29 주식회사 지티아이바이오사이언스 산화철 자성 입자의 제조방법

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205155B2 (en) * 2009-10-30 2015-12-08 General Electric Company Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
EP2383374A1 (en) 2010-04-29 2011-11-02 BASF Corporation Nano-particles containing carbon and a ferromagnetic metal or alloy
US9555136B2 (en) 2010-06-21 2017-01-31 University Of Washington Through Its Center For Commercialization Coated magnetic nanoparticles
EP2582400A4 (en) 2010-06-21 2016-05-25 Univ Washington Ct Commerciali MANIPULATED MULTIFUNCTIONAL MAGNETIC NANOPARTICLES FOR BIOMEDICINE
US8889103B2 (en) 2010-12-15 2014-11-18 General Electric Company Diagnostic agent composition and associated methods thereof
US8895068B2 (en) 2010-12-15 2014-11-25 General Electric Company Nanoparticle composition and associated methods thereof
US10012653B2 (en) 2011-06-15 2018-07-03 Board Of Regents, The University Of Texas System Nanoparticles for targeting acid tumor microenvironments
JP5844902B2 (ja) 2011-08-10 2016-01-20 マグフォース アーゲー アルコキシシランでコーティングされた磁性ナノ粒子の凝集化
US9017468B2 (en) 2012-04-25 2015-04-28 Hewlett-Packard Development Company, L.P. Colorant dispersion for an ink
US10953110B2 (en) 2014-04-25 2021-03-23 Board Of Regents, The University Of Texas System Dual emissive metal nanoparticles as ratiometric pH indicators
CN115699998B (zh) * 2020-05-26 2025-07-01 夏普株式会社 发光元件

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083902A2 (en) * 2002-10-25 2004-09-30 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
US20060093555A1 (en) * 2004-04-02 2006-05-04 Torres Andrew S Imaging inflammatory conditions using superparamagnetic iron oxide agents
JP2007112679A (ja) * 2005-10-21 2007-05-10 Fujifilm Corp ナノ粒子及びその製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797380B2 (en) * 2002-07-31 2004-09-28 General Electric Company Nanoparticle having an inorganic core
US7560160B2 (en) * 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
DE10331439B3 (de) * 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
US20050260137A1 (en) * 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US20060105052A1 (en) * 2004-11-15 2006-05-18 Acar Havva Y Cationic nanoparticle having an inorganic core
US7462446B2 (en) * 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
DE102005056620A1 (de) * 2005-11-25 2007-06-06 Merck Patent Gmbh Amphiphile Silane
WO2007070827A2 (en) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Contrast agents for myocardium perfusion imaging
US20070140974A1 (en) * 2005-12-15 2007-06-21 General Electric Company Targeted nanoparticles for magnetic resonance imaging

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083902A2 (en) * 2002-10-25 2004-09-30 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
US20060093555A1 (en) * 2004-04-02 2006-05-04 Torres Andrew S Imaging inflammatory conditions using superparamagnetic iron oxide agents
JP2007112679A (ja) * 2005-10-21 2007-05-10 Fujifilm Corp ナノ粒子及びその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013046070; Ｒａｎｄｙ　Ｄｅ　Ｐａｌｍａ　，　ｅｔ　ａｌ．: '"Ｓｕｒｆａｃｅ　Ｍｏｄｉｆｉｃａｔｉｏｎ　ｏｆ　gamma-Ｆｅ２Ｏ３＠ＳｉＯ２　Ｍａｇｎｅｔｉｃ　Ｎａｎｏｐａｒｔｉｃｌｅｓ　ｆｏｒ　ｔｈｅ　Ｃｏｎｔｒｏｌｌｅｄ　Ｉｎｔｅｒａｃｔｉｏｎ　ｗｉｔｈ　Ｂｉ' Ｊｏｕｒｎａｌ　ｏｆ　Ｎａｎｏｓｃｉｅｎｃｅ　ａｎｄ　Ｎａｎｏｔｅｃｈｎｏｌｏｇｙ ｖｏｌ．７, 200712, ｐｐ．４６２６-４６４１ *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102175448B1 (ko) * 2020-04-13 2020-11-06 주식회사 지티아이바이오사이언스 중원자-할로겐 화합물이 도핑된 산화철 자성 나노입자
KR102175449B1 (ko) * 2020-04-13 2020-11-06 주식회사 지티아이바이오사이언스 산화철/중원자-할로겐 화합물의 코어/쉘 구조 자성 나노입자
WO2021210776A1 (ko) * 2020-04-13 2021-10-21 주식회사 지티아이바이오사이언스 산화철 자성 입자
JP2022534883A (ja) * 2020-04-13 2022-08-04 ズィーティアイバイオサイエンス カンパニー リミテッド 酸化鉄磁性粒子
JP7262145B2 (ja) 2020-04-13 2023-04-21 ズィーティアイバイオサイエンス カンパニー リミテッド 酸化鉄磁性粒子
US11780739B2 (en) 2020-04-13 2023-10-10 Zti Biosciences Co., Ltd. Method for producing iron oxide magnetic particles, and iron oxide magnetic materials prepared thereby
US11795065B2 (en) 2020-04-13 2023-10-24 Zti Biosciences Co., Ltd. Iron oxide magnetic particles
WO2022270783A1 (ko) * 2021-06-23 2022-12-29 주식회사 지티아이바이오사이언스 산화철 자성 입자의 제조방법
KR20220170786A (ko) * 2021-06-23 2022-12-30 주식회사 지티아이바이오사이언스 산화철 자성 입자의 제조방법
KR20220170729A (ko) * 2021-06-23 2022-12-30 주식회사 지티아이바이오사이언스 산화철 자성 입자의 제조방법
KR102488840B1 (ko) 2021-06-23 2023-01-18 주식회사 지티아이바이오사이언스 산화철 자성 입자의 제조방법
KR102515402B1 (ko) 2021-06-23 2023-03-29 주식회사 지티아이바이오사이언스 산화철 자성 입자의 제조방법

Also Published As

Publication number Publication date
CN102083471A (zh) 2011-06-01
US20090226376A1 (en) 2009-09-10
WO2009109588A9 (en) 2009-11-05
WO2009109588A3 (en) 2010-07-22
WO2009109588A2 (en) 2009-09-11
EP2247315A2 (en) 2010-11-10
CN102083471B (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
US20090226376A1 (en) Novel Mixed Ligand Core/Shell Iron Oxide Nanoparticles for Inflammation Imaging
Zhang et al. Biocompatible superparamagnetic europium-doped iron oxide nanoparticle clusters as multifunctional nanoprobes for multimodal in vivo imaging
Xie et al. Iron oxide nanoparticle platform for biomedical applications
Sun et al. PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo
Mekuria et al. Encapsulation of gadolinium oxide nanoparticle (Gd2O3) contrasting agents in PAMAM dendrimer templates for enhanced magnetic resonance imaging in vivo
Muthiah et al. Surface modification of iron oxide nanoparticles by biocompatible polymers for tissue imaging and targeting
US20090280063A1 (en) Novel pei-peg graft copolymer coating of iron oxide nanoparticles for inflammation imaging
Yan et al. Recent advances in multifunctional magnetic nanoparticles and applications to biomedical diagnosis and treatment
Li et al. Facile one-pot synthesis of Fe3O4@ Au composite nanoparticles for dual-mode MR/CT imaging applications
Chekina et al. Fluorescent magnetic nanoparticles for biomedical applications
Li et al. Superparamagnetic iron oxide nanoparticles as MRI contrast agents for non-invasive stem cell labeling and tracking
Kim et al. A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle
JP5174654B2 (ja) 官能基化された磁性ナノ粒子およびその使用法
Zhang et al. Ultrasound-triggered BSA/SPION hybrid nanoclusters for liver-specific magnetic resonance imaging
JP5997609B2 (ja) 親水性のα−ヒドロキシホスホン酸コンジュゲートによる水不溶性ナノ粒子の処理、こうして修飾されたナノ粒子、及び造影剤としてのそれの使用
JP6174603B2 (ja) Ｔ２＊強調磁気共鳴イメージング（ｍｒｉ）のための造影剤
Xiao et al. Superparamagnetic iron oxide nanoparticles stabilized with multidentate block copolymers for optimal vascular contrast in T 1-weighted magnetic resonance imaging
US20060093555A1 (en) Imaging inflammatory conditions using superparamagnetic iron oxide agents
Yang et al. Cross-linked magnetic nanoparticles with a biocompatible amide bond for cancer-targeted dual optical/magnetic resonance imaging
JP2012044130A (ja) 正電荷性の超常磁性酸化鉄ナノ粒子と、これを利用した造影剤及びその製造方法
Mohammed et al. Bioactivity of hybrid polymeric magnetic nanoparticles and their applications in drug delivery
Slabu et al. Size-tailored biocompatible FePt nanoparticles for dual T1/T2 magnetic resonance imaging contrast enhancement
JP5185532B2 (ja) 中性媒質中に安定なフェロ流体、および変性された表面を有する粒子を用いたフェロ流体
Vishwasrao et al. Luteinizing hormone releasing hormone-targeted cisplatin-loaded magnetite nanoclusters for simultaneous MR imaging and chemotherapy of ovarian cancer
CN110013559A (zh) 一种ha靶向的双金属氢氧化物-超小铁纳米材料及其制备和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140311